title: Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers.
abstract: BACKGROUND
  This study was conducted in order to evaluate the significance of circulating free DNA (CFDNA), blood plasma p53 antibodies (p53-Ab) and mutations of KRAS gene in the prognosis of ovarian epithelial cancers.
  
  
  METHODS
  A total of 126 patients were included in this study. KRAS mutations and CFDNA were detected by means of the PCR-restriction fragment length polymorphism (PCR-RFLP) and enriched by the PCR-RFLP method. Enzyme-linked immunosorbent assay was used to analyze plasma p53-Ab.
  
  
  RESULTS
  KRAS mutations were detected in 27 (21.4%) of examined tumors. The frequency of KRAS mutations was especially high in mucinous cancers (P < 0.001). CFDNA and p53-Ab were frequently detected in patients with serous cancers in high grade (P < 0.001). The overall survival rate was significantly lower for patients with serous tumors and CFDNA and p53-Ab-positive than negative tumors (P = 0.022 and P < 0.001, respectively). In mucinous ovarian cancer, a worse overall survival was correlated with the KRAS mutations (P = 0.03).
  
  
  CONCLUSIONS
  The results of the present study suggested that a presence of KRAS mutations in mucinous ovarian cancer and CFDNA and p53-Ab in serous tumors was correlated with the highest risk of cancer progression.
authors.affiliation: Department of Obstetrics, Gynecology and Obstetrics/Gynecological Care, Medical University of Bialystok.
authors.forename: B
authors.initials: B
authors.lastname: Dobrzycka
authors.affiliation: Department of Obstetrics, Gynecology and Obstetrics/Gynecological Care, Medical University of Bialystok. Electronic address: sterlikowski@gmail.com.
authors.forename: S J
authors.initials: SJ
authors.lastname: Terlikowski
authors.affiliation: Department of Gynecology, District Hospital in Bialystok.
authors.forename: M
authors.initials: M
authors.lastname: Kinalski
authors.affiliation: Department of Clinical Molecular Biology.
authors.forename: O
authors.initials: O
authors.lastname: Kowalczuk
authors.affiliation: Department of Histology and Embryology.
authors.forename: W
authors.initials: W
authors.lastname: Niklinska
authors.affiliation: Department of Clinical Molecular Biology; Department of Pathomorphology, Medical University of Bialystok, Bialystok, Poland.
authors.forename: L
authors.initials: L
authors.lastname: Chyczewski
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000906:Antibodies / Q000097:blood*; D001483:Base Sequence; D014408:Biomarkers, Tumor / Q000097:blood*; D000077216:Carcinoma, Ovarian Epithelial; D004247:DNA / Q000097:blood*; D005260:Female; D056726:Genetic Association Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000097:blood / Q000175:diagnosis / Q000401:mortality; D010051:Ovarian Neoplasms / Q000097:blood / Q000175:diagnosis / Q000401:mortality; D017354:Point Mutation; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000235:genetics; D016283:Proto-Oncogene Proteins p21(ras); D017422:Sequence Analysis, DNA; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*; D055815:Young Adult; D018631:ras Proteins / Q000235:genetics
chemical_list: D000906:Antibodies; D014408:Biomarkers, Tumor; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D004247:DNA; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins